Review Article
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
Table 3
Lenalidomide containing regimens in relapsed/refractory indolent and mantle cell lymphoma.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*: data from patients enrolled in lenalidomide 20 mg/daily arm. No response was obtained for lower dosage. CT: chemotherapy; ORR: overall response rate; CR: complete response; RL: rituximab and lenalidomide; LD: lenalidomide and dexamethasone. |